Related Experiment Video
Updated: Jul 15, 2026
08:47
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Insulin resistance as a membrane microdomain disorder.
1Division of Glycopathology and CREST, Japan Science and Technology Agency, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University, Sendai, Japan. jin@tohoku-pharm.ac.jp
Summary
Increased ganglioside GM3 in membrane microdomains disrupts insulin receptor signaling, contributing to insulin resistance. This finding highlights GM3 as a potential therapeutic target for type 2 diabetes.
Area of Science:
- Cell Biology
- Metabolic Diseases
- Biochemistry
Background:
- Membrane microdomains, or lipid rafts, are crucial for insulin signaling compartmentalization.
- The role of microdomains in insulin resistance pathogenesis remains largely unexplored.
- Tumor necrosis factor-alpha (TNFα) is known to induce insulin resistance, but its precise mechanism is unclear.
Purpose of the Study:
- To investigate the role of membrane microdomains in insulin resistance.
- To elucidate the mechanism by which TNFα induces insulin resistance.
- To determine the specific function of the glycosphingolipid ganglioside GM3 in this process.
Main Methods:
- Isolation of detergent-resistant membrane microdomains (DRMs).
- Quantification of ganglioside GM3 levels in adipocytes and animal models.
- Analysis of insulin receptor (IR) and other protein accumulations in DRMs.
- Assessment of TNFα treatment effects on GM3 and IR levels.
- GM3 depletion experiments to evaluate its functional role.
Main Results:
- TNFα treatment selectively increased ganglioside GM3 levels in 3T3-L1 adipocytes.
- Elevated GM3 synthase mRNA levels were observed in the white adipose tissues of obese rats and mice.
- GM3 levels in DRMs doubled upon TNFα treatment, correlating with diminished insulin receptor (IR) accumulation.
- GM3 depletion reversed the TNFα-induced inhibition of IR accumulation into DRMs.
Conclusions:
- Accumulation of ganglioside GM3 in membrane microdomains contributes to insulin resistance.
- The loss of insulin receptors in microdomains due to GM3 accumulation underlies the insulin signaling defect.
- Targeting GM3 may offer a novel therapeutic strategy for managing insulin resistance and type 2 diabetes.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...